Here are five observations:
1. The FDA approved Viberzi at 75 mg and 100 mg for a 12-week treatment.
2. Patients suffering from IBS-D can take the pill twice a day.
3. Allergen’s stock rose 0.49 percent during the last trading session, reaching $293.22.
4. The company outperformed the S&P 500 by 9.6 percent.
5. Allergen develops medical aesthetics, generic, branded generic, biosimilar and over-the-counter pharmaceutical products.
More articles on gastroenterology:
GI physician leader to know: Dr. David Greenwald of Mount Sinai Hospital
Olympus’ modified duodenoscope receives FDA approval, EndoChoice stock lowered to “sell” & more — 4 GI/endoscopy company key notes
Are gastroenterologist’s patient biases & political leanings related? 4 statistics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.